Monday Aug 25
The American Journal of Managed Care
Potential Role of Network Meta-Analysis in Value-Based Insurance Design
James D. Chambers, PhD, MPharm, MSc; Aaron Winn, MPP; Yue Zhong, MD, PhD; Natalia Olchanski, MS; and Michael J. Cangelosi, MA, MPH Value-based insurance design has emerged as an approach to improve health outcomes and contain healthcare costs by encouraging use of high-value care.
Osteoporosis drugs destroy bones they are 'allegedly' designed to help
Sally Field, spokesperson for Roche pharmaceuticals has received $millions for falsely claiming that the bisphosphonate, Boniva, builds health bones, when in fact it destroys normal bone regulation and causes diseased and brittle bones.
Researchers at King Abdul-Aziz University Have Reported New Data on...
Targeting cancers within the bone marrow remains a crucial oncologic challenge due to issues of drug availability and microenvironment-induced resistance."
Bone Drugs Don't Lower Breast Cancer Risk After All, Study Finds
Drugs known as bisphosphonates, commonly prescribed to treat the bone-weakening disease osteoporosis, don't appear to reduce the risk of breast cancer as previously thought, new research finds.
Medical News Today
Bisphosphonates for osteoporosis not associated with reduced breast cancer risk
An analysis of data from two randomized clinical trials finds that three to four years of treatment with bisphosphonates to improve bone density is not linked to reduced risk of invasive postmenopausal breast cancer .
Bone drugs may not protect osteoporotic women from breast cancer
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco .